Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN011
MIFTS: 65

Adenoid Cystic Carcinoma

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases, Skin diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenoid Cystic Carcinoma

About this section

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma 12 12 76 53 6 73
Salivary Gland Adenoid Cystic Carcinoma 12 55 15
Cylindroma 12 53
Adenoid Cystic Carcinoma of Salivary Gland 73
Carcinoma, Adenoid Cystic 44
Eccrine Dermal Cylindroma 73
Carcinoma Adenoid Cystic 55
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 53
Carcinoma, Cribriform 73
Cribriform Carcinoma 53

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Oral diseases Gastrointestinal diseases Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080202 DOID:4866
MeSH 44 D003528
NCIt 50 C2970
Sources

Summaries for Adenoid Cystic Carcinoma

About this section
NIH Rare Diseases : 53 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook.

MalaCards based summary : Adenoid Cystic Carcinoma, also known as salivary gland adenoid cystic carcinoma, is related to breast adenoid cystic carcinoma and prostate adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Fentanyl and Doxepin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells.

Wikipedia : 76 Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Sources

Related Diseases for Adenoid Cystic Carcinoma

About this section

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 300)
# Related Disease Score Top Affiliating Genes
1 breast adenoid cystic carcinoma 35.2 ERBB2 KIT NFIB
2 prostate adenoid cystic carcinoma 35.0 HRAS PIK3CA
3 lung adenoid cystic carcinoma 34.1 FBXW7 HRAS KIT KRAS NFIB PIK3CA
4 pleomorphic adenoma 32.2 ERBB2 MUC1 TP53
5 polymorphous low-grade adenocarcinoma 32.0 CCND1 KIT MUC1 MYB NFIB
6 prostate cancer 31.5 CCND1 CHEK2 CREBBP ERBB2 FGFR4 HRAS
7 small cell carcinoma 31.3 KIT KRT7 PTEN TP53
8 epithelial-myoepithelial carcinoma 31.3 FBXW7 HRAS KRT7 TP53
9 mucoepidermoid carcinoma 31.1 ERBB2 KRT7 MUC1
10 gliosarcoma 31.0 IDH1 PTEN TP53
11 squamous cell carcinoma, head and neck 31.0 CCND1 ERBB2 HRAS PIK3CA PTEN TP53
12 necrotizing sialometaplasia 30.9 KIT KRT7 TP53
13 papilloma 30.8 CCND1 KRT7 PTEN TP53
14 teratoma 30.7 KIT KRT7 TP53
15 chromophobe renal cell carcinoma 30.7 CCND1 KIT KRT7
16 thymus cancer 30.7 KIT KRT7 MUC1 TP53
17 adenocarcinoma 30.7 CCND1 ERBB2 HRAS KIT KRAS MUC1
18 differentiated thyroid carcinoma 30.6 CHEK2 HRAS KRAS TP53
19 basal cell carcinoma 30.6 CYLD KRT7 PTEN TP53
20 spiradenoma 30.6 CYLD KRT7 MUC1 TP53
21 sarcoma, synovial 30.5 KIT KRT7 MUC1
22 papillary carcinoma 30.5 ERBB2 KRT7 MUC1
23 renal cell carcinoma, papillary, 1 30.4 ERBB2 HRAS KIT KRT7 PIK3CA PTEN
24 sarcoma 30.4 HRAS KIT KRAS PIK3CA TP53
25 squamous cell carcinoma 30.1 CCND1 ERBB2 FGFR4 HRAS KRAS MUC1
26 mucinous adenocarcinoma 30.0 KRAS KRT7 MUC1
27 lung cancer susceptibility 3 29.2 CCND1 ERBB2 HRAS IDH1 KRAS KRT7
28 breast cancer 28.6 CCND1 CHEK2 ERBB2 FBXW7 HRAS IDH1
29 cervical adenoid cystic carcinoma 12.4
30 trachea adenoid cystic carcinoma 12.4
31 maxillary sinus adenoid cystic carcinoma 12.4
32 lacrimal gland adenoid cystic carcinoma 12.4
33 esophageal adenoid cystic carcinoma 12.4
34 laryngeal adenoid cystic carcinoma 12.3
35 bartholin's gland adenoid cystic carcinoma 12.3
36 parotid gland adenoid cystic carcinoma 12.3
37 cribriform carcinoma 12.3
38 ethmoid sinus adenoid cystic carcinoma 12.2
39 adenoid cystic carcinoma of the corpus uteri 12.2
40 sublingual gland adenoid cystic carcinoma 12.1
41 lymph node adenoid cystic carcinoma 12.1
42 cutaneous adenocystic carcinoma 11.5
43 paranasal sinus cancer 11.4
44 adenoiditis 11.3
45 thyroid hurthle cell adenoma 11.2 PIK3CA PTEN
46 thymoma, familial 11.2 HRAS KIT
47 breast squamous cell carcinoma 11.2 ERBB2 PIK3CA TP53
48 esophagus adenocarcinoma 11.2 ERBB2 PIK3CA TP53
49 ovarian melanoma 11.2 HRAS KIT PTEN
50 synchronous bilateral breast carcinoma 11.2 CCND1 PTEN TP53

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:



Diseases related to Adenoid Cystic Carcinoma
Sources

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

About this section

UMLS symptoms related to Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 78)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.86 KRAS HRAS MUC1 PIK3CA
2 Decreased viability GR00106-A-0 10.86 KRAS
3 Decreased viability GR00221-A-1 10.86 KRAS KIT HRAS CYLD PIK3CA
4 Decreased viability GR00221-A-2 10.86 KRAS HRAS CHEK2 CYLD PIK3CA
5 Decreased viability GR00221-A-3 10.86 HRAS CHEK2
6 Decreased viability GR00221-A-4 10.86 CHEK2 PIK3CA
7 Decreased viability GR00301-A 10.86 KRAS KIT CYLD
8 Decreased viability GR00342-S-2 10.86 CHEK2
9 Decreased viability GR00381-A-1 10.86 KRAS
10 Decreased viability GR00402-S-2 10.86 KRAS KIT HRAS CHEK2 CYLD MUC1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.63 MYB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.63 NFIB
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.63 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.63 CHEK2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.63 NFIB
16 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.63 PIK3CA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.63 TP53
18 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.63 KRAS CHEK2 NOTCH1 MYB TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.63 FBXW7 MYB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.63 FBXW7 MYB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.63 CHEK2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.63 CCND1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.63 TP53
24 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.63 NOTCH1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.63 NOTCH1 MYB
26 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.63 CCND1 FBXW7
27 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.63 FBXW7 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.63 CCND1 PIK3CA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.63 MYB NOTCH1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.63 CCND1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.63 MYB
32 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.63 PIK3CA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.63 KRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.63 MYB TP53
35 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.63 KRAS CCND1 FBXW7 MYB NFIB PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.63 FBXW7
37 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.63 TP53
38 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.63 PIK3CA TP53
39 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.63 KRAS
40 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.63 CCND1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.63 NOTCH1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.63 CHEK2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.63 CCND1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.63 CCND1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.63 NOTCH1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.63 KRAS
47 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.63 CCND1 NFIB
48 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.63 NFIB TP53
49 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.63 CCND1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.63 TP53

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 TP53 PTEN CHEK2 CYLD CREBBP CCND1
2 endocrine/exocrine gland MP:0005379 10.48 TP53 PTEN CYLD CHEK2 CREBBP CCND1
3 homeostasis/metabolism MP:0005376 10.48 TP53 PTEN CHEK2 CYLD CREBBP CCND1
4 growth/size/body region MP:0005378 10.47 PIK3CA TP53 PTEN CYLD CREBBP CCND1
5 mortality/aging MP:0010768 10.43 TP53 PTEN CHEK2 CYLD CREBBP CCND1
6 digestive/alimentary MP:0005381 10.4 TP53 PTEN CYLD CREBBP CCND1 HRAS
7 cardiovascular system MP:0005385 10.39 PIK3CA TP53 PTEN CREBBP CCND1 ERBB2
8 immune system MP:0005387 10.38 PIK3CA TP53 PTEN CCND1 CHEK2 CYLD
9 hematopoietic system MP:0005397 10.37 TP53 PTEN CREBBP CCND1 CHEK2 CYLD
10 integument MP:0010771 10.34 TP53 PTEN CYLD CREBBP CCND1 HRAS
11 craniofacial MP:0005382 10.3 TP53 CCND1 CREBBP ERBB2 HRAS FBXW7
12 embryo MP:0005380 10.28 PIK3CA TP53 PTEN CREBBP ERBB2 FBXW7
13 neoplasm MP:0002006 10.28 TP53 PTEN CYLD CHEK2 CREBBP CCND1
14 nervous system MP:0003631 10.22 PIK3CA TP53 PTEN CREBBP CCND1 CHEK2
15 normal MP:0002873 10.15 TP53 PTEN CYLD CREBBP CCND1 ERBB2
16 liver/biliary system MP:0005370 10.1 TP53 PTEN CREBBP FBXW7 KIT KRAS
17 muscle MP:0005369 10.06 PTEN PIK3CA TP53 CREBBP ERBB2 KIT
18 limbs/digits/tail MP:0005371 10.05 PTEN TP53 CREBBP ERBB2 CYLD KIT
19 respiratory system MP:0005388 10 TP53 PTEN CYLD CREBBP CCND1 HRAS
20 renal/urinary system MP:0005367 9.8 PTEN TP53 HRAS KIT KRAS KRT7
21 skeleton MP:0005390 9.73 PIK3CA TP53 PTEN CCND1 CREBBP ERBB2
22 pigmentation MP:0001186 9.72 PTEN TP53 KIT KRAS NOTCH1
23 vision/eye MP:0005391 9.28 PIK3CA TP53 PTEN CCND1 FBXW7 KRAS
Sources

Drugs & Therapeutics for Adenoid Cystic Carcinoma

About this section

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
3
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
4
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
5
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
6
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
7
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
8
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
9 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
10 Porfiromycin Investigational Phase 3 801-52-5
11 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
12 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
14 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
15 Adjuvants, Anesthesia Phase 3
16 Analgesics Phase 3
17 Analgesics, Opioid Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Central Nervous System Depressants Phase 3
22 Narcotics Phase 3
23 Peripheral Nervous System Agents Phase 3,Not Applicable
24 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
25 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
26 Mitomycins Phase 3
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
28 Antidepressive Agents Phase 3
29 Antidepressive Agents, Tricyclic Phase 3
30 Histamine Antagonists Phase 3
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Neurotransmitter Agents Phase 3,Not Applicable
33 Psychotropic Drugs Phase 3
34 Antifungal Agents Phase 2, Phase 3,Phase 1
35 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
36 Hormone Antagonists Phase 2, Phase 3
37 Hormones Phase 2, Phase 3,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
39 Steroid Synthesis Inhibitors Phase 2, Phase 3
40 Autonomic Agents Phase 3,Not Applicable
41 Cholinergic Agents Phase 3,Not Applicable
42 Antineoplastic Agents, Hormonal Phase 3
43 Appetite Stimulants Phase 3
44 Central Nervous System Stimulants Phase 3,Not Applicable
45 Contraceptive Agents Phase 3
46 Contraceptives, Oral Phase 3
47
Megestrol Phase 3 3562-63-8 19090 3080587
48 Antimitotic Agents Phase 3,Phase 2,Phase 1
49 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
50
Cetuximab Approved Phase 1, Phase 2,Phase 2 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
3 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
4 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
6 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
8 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
9 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
10 Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT00180921 Phase 2 Imatinib
11 Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
12 Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Unknown status NCT02857712 Phase 2 Axitinib
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 Study of RAD001 in Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
15 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
16 Dovitinib in Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
17 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00581360 Phase 2 doxorubicin and bortezomib
18 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
19 Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Completed NCT01524692 Phase 2 Dovitinib (TKI258)
20 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
21 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
22 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
23 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
24 Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
25 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00859937 Phase 2 Dasatinib
26 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
27 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
28 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
29 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
30 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
31 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
32 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
33 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
34 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
35 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
36 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
37 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
38 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
39 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
40 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
41 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
42 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
43 Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Recruiting NCT03087019 Phase 2 Pembrolizumab
44 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Recruiting NCT02883374 Phase 2 Chidamide
45 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer Recruiting NCT03146650 Phase 2
46 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
47 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab
48 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
49 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting NCT03422679 Phase 1, Phase 2 CB-103
50 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages Recruiting NCT03274414 Phase 2 Cisplatin

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Sources

Genetic Tests for Adenoid Cystic Carcinoma

About this section
Sources

Anatomical Context for Adenoid Cystic Carcinoma

About this section

MalaCards organs/tissues related to Adenoid Cystic Carcinoma:

41
Salivary Gland, Breast, Lung, Brain, Trachea, Lymph Node, Uterus
Sources

Publications for Adenoid Cystic Carcinoma

About this section

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 863)
# Title Authors Year
1
Cervical lymph node metastases in salivary gland adenoid cystic carcinoma: a systematic review and meta-analysis. ( 29970966 )
2018
2
Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study. ( 29850151 )
2018
3
Liver resection for metastases of tracheal adenoid cystic carcinoma: Report of two cases. ( 29778031 )
2018
4
Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. ( 29731974 )
2018
5
Central airway obstruction caused by adenoid cystic carcinoma in pregnancy: a case report and review of the literature. ( 29721318 )
2018
6
Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells. ( 29710459 )
2018
7
Deregulation of Nicotinamide N-Methyltransferase and Gap Junction Protein Alpha-1 Causes Metastasis in Adenoid Cystic Carcinoma. ( 29277772 )
2018
8
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. ( 29954240 )
2018
9
Ataxia-Telangiectasia-Mutated Protein Expression as a Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands. ( 29978608 )
2018
10
Discordant correlation of breast adenoid cystic carcinoma on imaging and pathology: A case report and literature review on surgical management. ( 29268125 )
2018
11
Potential biological functions of microvesicles derived from adenoid cystic carcinoma. ( 29725477 )
2018
12
Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis. ( 29399171 )
2018
13
3D-printing aided resection of intratracheal adenoid cystic carcinoma and mediastinal mature cystic teratoma in a 26-year-old female: a case report. ( 29607203 )
2018
14
miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L. ( 29760585 )
2018
15
Dedifferentiated adenoid cystic carcinoma ex pleomorphic adenoma of the parotid. ( 29893347 )
2018
16
Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival. ( 29858025 )
2018
17
IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-I_B/ZEB1 signaling pathway. ( 29885520 )
2018
18
Immunohistochemical Expression of CD-117 (c-KIT), P-53 and Ki-67 in Adenoid Cystic Carcinoma of Palate. ( 29866247 )
2018
19
Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma. ( 29956779 )
2018
20
Primary Cutaneous Adenoid Cystic Carcinoma Connecting to the Epidermis. ( 29742556 )
2018
21
Sinonasal adenoid cystic carcinoma-role of on-site FNAC: a case report. ( 29760580 )
2018
22
Establishment and characterization of a carcinoma-associated fibroblast cell line derived from a human salivary gland adenoid cystic carcinoma. ( 29734861 )
2018
23
Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression. ( 29924420 )
2018
24
A Case of Adenoid Cystic Carcinoma Mimicking a Bartholin Cyst and Literature Review. ( 29780648 )
2018
25
Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern china: A 25-year retrospective study. ( 28151884 )
2017
26
Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776. ( 28228352 )
2017
27
Clinicopathological characteristics of KIT and protein kinase C-I' expression in adenoid cystic carcinoma: comparison with chromophobe renal cell carcinoma and gastrointestinal stromal tumour. ( 28561935 )
2017
28
Early stage minor salivary gland adenoid cystic carcinoma has favourable prognosis. ( 28600602 )
2017
29
Mithramycin inhibits epithelial-to-mesenchymal transition and invasion by downregulating SP1 and SNAI1 in salivary adenoid cystic carcinoma. ( 28631560 )
2017
30
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. ( 27870570 )
2017
31
MYB Labeling by Immunohistochemistry Is More Sensitive and Specific for Breast Adenoid Cystic Carcinoma than MYB Labeling by FISH. ( 28498281 )
2017
32
B7-H3 regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway. ( 28386362 )
2017
33
Correction: Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. ( 28642227 )
2017
34
HIF1I+ in Tumorigenesis of Adenoid Cystic Carcinoma. ( 28179306 )
2017
35
Breast adenoid cystic carcinoma: report of a case with emphasis on routine sonographic findings and shear wave elastography. ( 28382475 )
2017
36
Adenoid Cystic Carcinoma of Maxillary Sinus Misdiagnosed as Chronic Apical Periodontitis. ( 28236426 )
2017
37
Knockdown of SKA1 gene inhibits cell proliferation and metastasis in human adenoid cystic carcinoma. ( 28340379 )
2017
38
MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. ( 28594149 )
2017
39
Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma. ( 28820917 )
2017
40
c-Myb Overexpression in Cytology Smears of Tracheobronchial and Pulmonary Adenoid Cystic Carcinomas. ( 27974718 )
2017
41
Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. ( 27662035 )
2017
42
Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma. ( 28152077 )
2017
43
The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. ( 29266837 )
2017
44
Breast Adenoid Cystic Carcinoma: A Rare Case Report and Review of the Literature. ( 28798006 )
2017
45
Diagnostic utility of C-kit protein (CD117) expression in differentiating adenoid cystic carcinoma and polymorphous low grade Adenocarcinoma. ( 29492062 )
2017
46
Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. ( 27550999 )
2017
47
Endoscopic submucosal dissection in a patient with esophageal adenoid cystic carcinoma. ( 29259386 )
2017
48
Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma. ( 28914715 )
2017
49
Garcin syndrome caused by parotid gland adenoid cystic carcinoma: A case report. ( 29137049 )
2017
50
Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement. ( 28085142 )
2017
Sources

Variations for Adenoid Cystic Carcinoma

About this section

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

6
(show top 50) (show all 116)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
2 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
3 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
4 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
5 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
6 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
7 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
8 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
9 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
10 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
11 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
13 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
14 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 GRCh38 Chromosome 3, 179210192: 179210192
15 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
16 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
17 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
18 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
19 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
20 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
21 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
22 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
23 JAK3 NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser) single nucleotide variant Pathogenic rs886039394 GRCh37 Chromosome 19, 17947959: 17947959
24 JAK3 NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser) single nucleotide variant Pathogenic rs886039394 GRCh38 Chromosome 19, 17837150: 17837150
25 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
26 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
27 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
28 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
29 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
30 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
31 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
32 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
33 PIK3CA NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys) single nucleotide variant Likely pathogenic rs121913284 GRCh37 Chromosome 3, 178921553: 178921553
34 PIK3CA NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys) single nucleotide variant Likely pathogenic rs121913284 GRCh38 Chromosome 3, 179203765: 179203765
35 CREBBP NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu) single nucleotide variant Likely pathogenic rs1057519884 GRCh37 Chromosome 16, 3788617: 3788617
36 CREBBP NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu) single nucleotide variant Likely pathogenic rs1057519884 GRCh38 Chromosome 16, 3738616: 3738616
37 CREBBP NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His) single nucleotide variant Likely pathogenic rs1057519884 GRCh37 Chromosome 16, 3788617: 3788617
38 CREBBP NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His) single nucleotide variant Likely pathogenic rs1057519884 GRCh38 Chromosome 16, 3738616: 3738616
39 CREBBP NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly) single nucleotide variant Likely pathogenic rs398124146 GRCh37 Chromosome 16, 3788618: 3788618
40 CREBBP NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly) single nucleotide variant Likely pathogenic rs398124146 GRCh38 Chromosome 16, 3738617: 3738617
41 FBXW7 NM_018315.4(FBXW7): c.1153C> T (p.Arg385Cys) single nucleotide variant Likely pathogenic rs867384286 GRCh37 Chromosome 4, 153249385: 153249385
42 FBXW7 NM_018315.4(FBXW7): c.1153C> T (p.Arg385Cys) single nucleotide variant Likely pathogenic rs867384286 GRCh38 Chromosome 4, 152328233: 152328233
43 FBXW7 NM_018315.4(FBXW7): c.1154G> A (p.Arg385His) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
44 FBXW7 NM_018315.4(FBXW7): c.1154G> A (p.Arg385His) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232
45 FBXW7 NM_018315.4(FBXW7): c.1154G> C (p.Arg385Pro) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
46 FBXW7 NM_018315.4(FBXW7): c.1154G> C (p.Arg385Pro) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232
47 FBXW7 NM_001013415.1(FBXW7): c.1040G> T (p.Arg347Leu) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
48 FBXW7 NM_001013415.1(FBXW7): c.1040G> T (p.Arg347Leu) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232
49 FBXW7 NM_001013415.1(FBXW7): c.1039C> G (p.Arg347Gly) single nucleotide variant Likely pathogenic rs867384286 GRCh37 Chromosome 4, 153249385: 153249385
50 FBXW7 NM_001013415.1(FBXW7): c.1039C> G (p.Arg347Gly) single nucleotide variant Likely pathogenic rs867384286 GRCh38 Chromosome 4, 152328233: 152328233

Cosmic variations for Adenoid Cystic Carcinoma:

9
(show top 50) (show all 14021)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6939530 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 28
2 COSM6939527 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 28
3 COSM43878 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.427G>A p.V143M 17:7675185-7675185 28
4 COSM10777 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.715A>G p.N239D 17:7674248-7674248 28
5 COSM6935085 TENT5C salivary gland,minor,carcinoma,adenoid cystic carcinoma c.833T>A p.F278Y 1:117623701-117623701 28
6 COSM6939534 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 28
7 COSM6939532 SOX9 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1457T>A p.V486D 17:72124314-72124314 28
8 COSM6939526 SMO salivary gland,major,carcinoma,adenoid cystic carcinoma c.385G>C p.V129L 7:129203437-129203437 28
9 COSM6915408 SF3B1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.3254C>T p.A1085V 2:197397997-197397997 28
10 COSM6910358 SETD2 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.4870C>T p.Q1624* 3:47057405-47057405 28
11 COSM41699 RUNX1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.958C>T p.R320* 21:34799310-34799310 28
12 COSM6928612 RPTOR salivary gland,minor,carcinoma,adenoid cystic carcinoma c.734C>T p.A245V 17:80754089-80754089 28
13 COSM1644939 RB1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1817A>G p.Y606C 13:48456206-48456206 28
14 COSM6913929 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2603+2T>A p.? 5:87379852-87379852 28
15 COSM6910894 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.3026T>G p.L1009R 5:87389493-87389493 28
16 COSM6910364 RARA salivary gland,minor,carcinoma,adenoid cystic carcinoma c.691C>G p.L231V 17:40352391-40352391 28
17 COSM1110409 PTPRD salivary gland,major,carcinoma,adenoid cystic carcinoma c.5473G>C p.G1825R 9:8331643-8331643 28
18 COSM3219585 PTPRD salivary gland,major,carcinoma,adenoid cystic carcinoma c.3542G>A p.R1181H 9:8465638-8465638 28
19 COSM5046 PTEN salivary gland,major,carcinoma,adenoid cystic carcinoma c.764T>C p.V255A 10:87957982-87957982 28
20 COSM51211 PPP2R1A salivary gland,major,carcinoma,adenoid cystic carcinoma c.547C>T p.R183W 19:52212729-52212729 28
21 COSM6935088 PIK3CG salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2951C>A p.P984Q 7:106886213-106886213 28
22 COSM757 PIK3CA salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1258T>C p.C420R 3:179210192-179210192 28
23 COSM6960739 PIK3C2G salivary gland,major,carcinoma,adenoid cystic carcinoma c.1852C>G p.P618A 12:18381860-18381860 28
24 COSM6939528 PGR salivary gland,major,carcinoma,adenoid cystic carcinoma c.1604C>G p.P535R 11:101127467-101127467 28
25 COSM6959277 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2158A>T p.T720S 9:84955503-84955503 28
26 COSM6916607 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2336T>C p.I779T 9:85021256-85021256 28
27 COSM6909937 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.973A>G p.N325D 9:136518717-136518717 28
28 COSM6916910 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.403+1G>C p.? 9:136523716-136523716 28
29 COSM13044 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.5101G>C p.A1701P 9:136503248-136503248 28
30 COSM3929943 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1367G>A p.C456Y 9:136517826-136517826 28
31 COSM13081 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.7400C>A p.S2467* 9:136496339-136496339 28
32 COSM6910892 MYCN salivary gland,major,carcinoma,adenoid cystic carcinoma c.1336A>G p.K446E 2:15946038-15946038 28
33 COSM6911643 MET salivary gland,major,carcinoma,adenoid cystic carcinoma c.1249C>G p.R417G 7:116731716-116731716 28
34 COSM6910361 MAX salivary gland,minor,carcinoma,adenoid cystic carcinoma c.295+1G>A p.? 14:65077912-65077912 28
35 COSM4042348 KMT2D salivary gland,minor,carcinoma,adenoid cystic carcinoma c.12640C>T p.R4214* 12:49031255-49031255 28
36 COSM6927891 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.3587G>A p.W1196* 12:49046621-49046621 28
37 COSM6909196 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.9308C>A p.S3103* 12:49037238-49037238 28
38 COSM51381 KIT salivary gland,face,carcinoma,adenoid cystic carcinoma c.2386A>G p.R796G 4:54733094-54733094 28
39 COSM5609233 KDR salivary gland,major,carcinoma,adenoid cystic carcinoma c.2524C>T p.R842C 4:55097752-55097752 28
40 COSM6911645 KDM6A salivary gland,major,carcinoma,adenoid cystic carcinoma c.3625A>G p.R1209G 23:45089819-45089819 28
41 COSM5696749 KDM6A salivary gland,major,carcinoma,adenoid cystic carcinoma c.3736+2T>C p.? 23:45089932-45089932 28
42 COSM6955991 KDM5A salivary gland,major,carcinoma,adenoid cystic carcinoma c.1186C>T p.R396W 12:350743-350743 28
43 COSM6913928 JAK1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.3310C>T p.L1104F 1:64835455-64835455 28
44 COSM6925975 HGF salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1444+1G>A p.? 7:81711480-81711480 28
45 COSM6910893 FOXP1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1930G>T p.E644* 3:70959351-70959351 28
46 COSM6910360 FGFR3 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1682G>C p.G561A 4:1805786-1805786 28
47 COSM6916439 EZH2 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.938G>A p.R313Q 7:148819657-148819657 28
48 COSM6935087 ETV1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.971G>T p.R324L 7:13906569-13906569 28
49 COSM6938635 ERBB3 salivary gland,major,carcinoma,adenoid cystic carcinoma c.917C>G p.P306R 12:56088585-56088585 28
50 COSM6955992 ERBB2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2126A>T p.Q709L 17:39723578-39723578 28

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma
Sources

Expression for Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.
Sources

Pathways for Adenoid Cystic Carcinoma

About this section

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 14.27 CCND1 CREBBP CYLD ERBB2 FBXW7 FGFR4
2
Innate Immune System 66
Show member pathways
 14.09 CCND1 CREBBP CYLD ERBB2 FBXW7 FGFR4
3
ERK Signaling 64
Show member pathways
 13.93 CCND1 CHEK2 CREBBP ERBB2 FGFR4 HRAS
4
GPCR Pathway 64
Show member pathways
 13.81 CCND1 CREBBP ERBB2 FGFR4 HRAS JAK3
5
HIV Life Cycle 66
Show member pathways
 13.8 CREBBP ERBB2 FBXW7 FGFR4 HRAS IDH1
6
TGF-Beta Pathway 64
Show member pathways
 13.61 CREBBP ERBB2 FGFR4 HRAS JAK3 KIT
7
Developmental Biology 66
Show member pathways
 13.59 CREBBP ERBB2 FGFR4 HRAS JAK3 KIT
8
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.55 ERBB2 FBXW7 FGFR4 HRAS KIT KRAS
9
Akt Signaling 64
Show member pathways
 13.5 CCND1 ERBB2 FGFR4 HRAS JAK3 KIT
10
Cytokine Signaling in Immune system 66
Show member pathways
 13.45 CCND1 ERBB2 FGFR4 HRAS JAK3 KIT
11
CREB Pathway 64
Show member pathways
 13.41 CREBBP ERBB2 FGFR4 HRAS KIT KRAS
12
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.41 CREBBP HRAS JAK3 KRAS MYB PIK3CA
13
PAK Pathway 64
Show member pathways
 13.39 CREBBP ERBB2 FGFR4 HRAS KIT KRAS
14
PI3K/AKT activation 66
Show member pathways
 13.2 ERBB2 FGFR4 KIT PIK3CA PTEN TP53
15
Phospholipase-C Pathway 64
Show member pathways
 13.15 CREBBP FGFR4 HRAS KIT KRAS PTEN
16
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 13 CCND1 HRAS JAK3 KRAS PIK3CA PTEN
17
Focal Adhesion 37 1
Show member pathways
 12.99 CCND1 ERBB2 HRAS KRAS PIK3CA PTEN
18
CCR5 Pathway in Macrophages 64
Show member pathways
 12.97 CCND1 CREBBP HRAS JAK3 KRAS PIK3CA
19
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.96 CREBBP ERBB2 FGFR4 HRAS JAK3 KRAS
20
Endometrial cancer 37
Show member pathways
 12.93 CCND1 CREBBP ERBB2 HRAS KIT KRAS
21
ErbB4 Pathway 64
Show member pathways
 12.89 CCND1 CREBBP ERBB2 HRAS JAK3 KRAS
22
Influenza A 37
Show member pathways
 12.88 CCND1 CREBBP JAK3 PIK3CA TP53
23
MAPK signaling pathway 1 37
12.86 ERBB2 FGFR4 HRAS KIT KRAS TP53
24
Glioma 37
Show member pathways
 12.83 CCND1 ERBB2 HRAS JAK3 KRAS NOTCH1
25
Ras signaling pathway 37
Show member pathways
 12.82 FGFR4 HRAS KIT KRAS PIK3CA
26
Development HGF signaling pathway 22
Show member pathways
 12.81 ERBB2 HRAS KRAS PIK3CA PTEN TP53
27
Gastric cancer 37
Show member pathways
 12.81 CCND1 ERBB2 HRAS KIT KRAS NOTCH1
28
PI3K-Akt signaling pathway 37
Show member pathways
 12.8 CCND1 CREBBP ERBB2 FGFR4 HRAS JAK3
29
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.79 ERBB2 FGFR4 HRAS KIT KRAS PIK3CA
30
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.76 CCND1 HRAS KRAS PIK3CA PTEN
31
4-1BB Pathway 64
Show member pathways
 12.76 CREBBP HRAS JAK3 KRAS TP53
32
Pathways in cancer 37
12.76 CCND1 CREBBP ERBB2 FGFR4 HRAS JAK3
33
Regulation of IFNA signaling 66
Show member pathways
 12.73 CCND1 CREBBP HRAS JAK3 PIK3CA
34
Immune response IL-23 signaling pathway 22
Show member pathways
 12.69 ERBB2 HRAS KRAS PIK3CA TP53
35
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.67 CCND1 CREBBP HRAS KRAS PIK3CA PTEN
36
Development EGFR signaling pathway 22
Show member pathways
 12.63 CCND1 ERBB2 HRAS KRAS MUC1 PIK3CA
37
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.6 ERBB2 FGFR4 HRAS KRAS PIK3CA PTEN
38
Prolactin Signaling Pathway 1 37
Show member pathways
 12.58 CCND1 CREBBP ERBB2 HRAS KRAS PIK3CA
39
ErbB signaling pathway 1 37
Show member pathways
 12.57 CCND1 CREBBP ERBB2 HRAS KRAS PIK3CA
40
Apoptosis Pathway 72
Show member pathways
 12.52 CHEK2 ERBB2 FGFR4 HRAS KRAS PIK3CA
41
MicroRNAs in cancer 37
12.5 CCND1 CREBBP ERBB2 HRAS KRAS NOTCH1
42
Phospholipase D signaling pathway 37
Show member pathways
 12.48 HRAS KIT KRAS PIK3CA
43
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.48 HRAS JAK3 KRAS PIK3CA
44
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.46 HRAS KRAS PIK3CA PTEN
45
DNA Damage Response 1
Show member pathways
 12.46 CCND1 CHEK2 PTEN TP53
46
Cell cycle 1 37
12.45 CCND1 CHEK2 CREBBP TP53
47
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.42 CCND1 CREBBP ERBB2 HRAS PIK3CA
48
B Cell Receptor Signaling Pathway (sino) 67
Show member pathways
 12.41 HRAS KRAS PIK3CA PTEN
49
Proteoglycans in cancer 37
12.41 CCND1 ERBB2 HRAS KRAS PIK3CA TP53
50
Signaling by ERBB2 66
Show member pathways
 12.4 ERBB2 HRAS KRAS PIK3CA
Sources

GO Terms for Adenoid Cystic Carcinoma

About this section

Cellular components related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 CCND1 CYLD ERBB2 FBXW7 HRAS IDH1
2 cytoplasm GO:0005737 9.55 CCND1 CREBBP CYLD ERBB2 FBXW7 FGFR4
3 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.43 CYLD JAK3 KRAS
4 receptor complex GO:0043235 9.26 ERBB2 FGFR4 KIT NOTCH1

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.96 FGFR4 NOTCH1 PIK3CA PTEN
2 cell migration GO:0016477 9.96 FGFR4 JAK3 PIK3CA PTEN
3 positive regulation of cell proliferation GO:0008284 9.91 CCND1 FGFR4 HRAS KIT KRAS NOTCH1
4 protein autophosphorylation GO:0046777 9.89 CHEK2 ERBB2 FGFR4 KIT
5 peptidyl-tyrosine phosphorylation GO:0018108 9.88 ERBB2 FGFR4 JAK3 KIT
6 positive regulation of protein kinase B signaling GO:0051897 9.86 ERBB2 FGFR4 KIT PIK3CA
7 positive regulation of MAPK cascade GO:0043410 9.85 ERBB2 FGFR4 HRAS KIT
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.84 CREBBP HRAS KRAS MUC1
9 Ras protein signal transduction GO:0007265 9.83 HRAS KRAS TP53
10 positive regulation of kinase activity GO:0033674 9.81 ERBB2 FGFR4 KIT
11 phosphatidylinositol phosphorylation GO:0046854 9.81 ERBB2 FGFR4 KIT PIK3CA
12 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.8 CHEK2 MUC1 TP53
13 liver development GO:0001889 9.8 CCND1 KRAS NOTCH1 PIK3CA
14 positive regulation of protein phosphorylation GO:0001934 9.8 CCND1 CHEK2 ERBB2 HRAS KRAS
15 MAPK cascade GO:0000165 9.8 ERBB2 FGFR4 HRAS JAK3 KIT KRAS
16 positive regulation of epithelial cell proliferation GO:0050679 9.79 ERBB2 HRAS NOTCH1
17 epidermal growth factor receptor signaling pathway GO:0007173 9.79 HRAS KRAS PIK3CA
18 positive regulation of Notch signaling pathway GO:0045747 9.74 CREBBP KIT NOTCH1
19 positive regulation of MAP kinase activity GO:0043406 9.73 ERBB2 HRAS KIT KRAS
20 cellular response to gamma radiation GO:0071480 9.7 CHEK2 HRAS TP53
21 positive regulation of gene expression GO:0010628 9.7 ERBB2 FGFR4 HRAS KIT KRAS PTEN
22 enzyme linked receptor protein signaling pathway GO:0007167 9.66 ERBB2 JAK3
23 somatic stem cell division GO:0048103 9.65 KIT NOTCH1
24 mitotic G1 DNA damage checkpoint GO:0031571 9.64 CCND1 TP53
25 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.63 CHEK2 MUC1 TP53
26 response to isolation stress GO:0035900 9.61 HRAS KRAS
27 ERBB2 signaling pathway GO:0038128 9.56 ERBB2 HRAS KRAS PIK3CA
28 cytokine-mediated signaling pathway GO:0019221 9.5 CCND1 JAK3 KIT KRAS MUC1 PIK3CA
29 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.17 ERBB2 FBXW7 FGFR4 HRAS KIT NOTCH1
30 cell differentiation GO:0030154 10.12 ERBB2 FGFR4 JAK3 KIT MYB NOTCH1
31 negative regulation of transcription by RNA polymerase II GO:0000122 10.11 CCND1 CREBBP MYB NFIB NOTCH1 TP53
32 phosphorylation GO:0016310 10.08 CHEK2 ERBB2 FGFR4 JAK3 KIT PIK3CA
33 negative regulation of cell proliferation GO:0008285 10.03 HRAS NFIB NOTCH1 PTEN TP53
34 protein phosphorylation GO:0006468 10.02 CCND1 CHEK2 ERBB2 FGFR4 JAK3 KIT

Molecular functions related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.85 CCND1 CHEK2 CYLD PTEN TP53
2 protein kinase activity GO:0004672 9.8 CCND1 CHEK2 ERBB2 FGFR4 JAK3 KIT
3 MAP kinase kinase kinase activity GO:0004709 9.71 ERBB2 FGFR4 KIT
4 protein tyrosine kinase activity GO:0004713 9.71 ERBB2 FGFR4 JAK3 KIT
5 kinase activity GO:0016301 9.7 CCND1 CHEK2 ERBB2 FGFR4 JAK3 KIT
6 protein phosphatase binding GO:0019903 9.69 ERBB2 JAK3 TP53
7 p53 binding GO:0002039 9.67 CREBBP MUC1 TP53
8 mitogen-activated protein kinase kinase binding GO:0031434 9.65 ERBB2 FGFR4 KIT
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.61 ERBB2 FGFR4 KIT
10 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.56 ERBB2 FGFR4 JAK3 KIT
11 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.52 ERBB2 KIT
12 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 ERBB2 FGFR4 KIT PIK3CA
13 nucleotide binding GO:0000166 9.17 CHEK2 ERBB2 FGFR4 HRAS JAK3 KIT
14 protein binding GO:0005515 10.32 CCND1 CHEK2 CREBBP CYLD ERBB2 FBXW7
Sources

Sources for Adenoid Cystic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....